Breast Cancer

Inquiry

Breast cancer is a complex and highly challenging disease affecting a large number of women worldwide. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for breast cancer animal model construction, pharmacodynamic evaluation, mammary fat pad orthotopic model validation, lung/brain/bone metastasis evaluation, postoperative recurrence studies, tumor immune profiling, target expression validation, pathological examination, molecular mechanism testing, and PK/PD, tailored to clients' candidate drugs, molecular subtypes, target expression, metastatic organs, immune system requirements, routes of administration, and R&D stages. In addition, we offer zebrafish experimental services and cell-based experimental services to meet diverse research needs ranging from in vitro to in vivo and from high-throughput screening to mechanism validation.

Introduction to Breast Cancer

Breast cancer is a malignant tumor originating from the mammary epithelium and is one of the most prevalent malignancies among women globally. Breast cancer is highly heterogeneous, with significant differences in molecular subtype, driver genes, hormone receptor status, HER2 expression, immune microenvironment, and metastatic organ preference. Clinically, breast cancer is commonly classified based on ER, PR, HER2, and Ki67 status into subtypes such as Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC). Treatment strategies and prognoses differ markedly across subtypes: HR+/HER2- breast cancer is primarily managed with endocrine therapy and CDK4/6 inhibitors; HER2-positive breast cancer relies on HER2-targeted agents and ADCs as core therapies; and TNBC depends more heavily on chemotherapy, immunotherapy, TROP2 ADCs, and PARP inhibitors. Common metastatic sites of breast cancer include lymph nodes, bone, lung, liver, and brain. Among these, bone metastasis and brain metastasis are high-priority scenarios in clinical translational research and important directions requiring dedicated modeling in drug evaluation. The immune microenvironment, tumor-infiltrating lymphocytes, TAMs, MDSCs, and cytokine networks in breast cancer play important roles in therapeutic response and drug resistance.

Fig.2 Types of Breast Cancer.

Therapy Development for Breast Cancer

Targets	Current Therapies
Key cell surface receptors	Anti-HER2 monoclonal antibodies (trastuzumab, pertuzumab, and margetuximab) Antibody-drug conjugates (ADCs), trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd)
Trop2	ADCs (sacituzumab govitecan)
PD-L1	Atezolizumab, durvalumab, and avelumab
CTLA-4	Ipilimumab and tremelimumab
HER2	Tyrosine kinase inhibitors such as lapatinib, neratinib, and tucatinib.
MEK, PI3K, and AKT	MEK, PI3K, and AKT inhibitors are under investigation.
ER modulators (SERMS) or aromatase inhibitors (AIs)	Block estradiol production for ER+ breast cancer.
PARP	The targeting of single-strand DNA breaks in BRCA1/BRCA2 mutation carriers with PARP inhibitors is in clinical practice.

Our Services

Alfa Cytology has established a comprehensive solution platform for breast cancer animal experimental research, built around HR+/HER2- endocrine dependence and resistance, HER2-positive and HER2-low targeted therapy, TNBC invasion and metastasis, mammary fat pad orthotopic microenvironment, lung/brain/bone organ-specific metastasis, ADCs, immunotherapy, humanized immunotherapy, and postoperative relapse/MRD scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full breast cancer research workflow.

Preclinical Efficacy Studies

Breast cancer drug development requires model selection based on molecular subtype, driver gene, target expression, immune requirements, and metastatic organ scenario. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for endocrine therapy, SERDs, ER degraders, CDK4/6 inhibitors, HER2-targeted agents, HER2 ADCs, TROP2 ADCs, chemotherapy, immune checkpoint inhibitors, STING, TCEs, CAR-T/NK, local delivery, and resistance/relapse programs.

Candidate Screening

Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, and target pathway evaluations using molecular subtype-matched subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.

Clinical Relevance Studies

When programs advance to breast orthotopic, lung metastasis, brain metastasis, bone metastasis, immunotherapy, humanized immunotherapy, local delivery, or resistance/relapse stages, Alfa Cytology can further provide orthotopic models, metastasis models, syngeneic immunocompetent models, or humanized immune models to help clients generate evidence more aligned with clinical scenarios.

Breast Cancer Mechanism Research

For breast cancer studies, experimental design typically needs to address cell line stratification, driver genes, breast microenvironment, metastatic organs, and immune microenvironment simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering ER resistance, HER2 pathway, TROP2-related mechanisms, TNBC invasion, lung/brain/bone metastasis, systemic dissemination, TME, resistance/relapse, and combination therapy mechanisms.

In Vitro and In Vivo Layered Validation

Animal studies can evaluate whether a candidate inhibits tumor growth, local invasion, organ metastasis, or immune evasion; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, metastatic invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, target expression, drug internalization, resistance mechanisms, and immune killing.

Molecular Mechanism Studies

Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, target expression validation, tumor immune profiling, PK/PD, tumor tissue drug concentration, brain tissue exposure, and bone tissue exposure testing.

For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation，translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:

Supported R&D Programs

R&D Project	Cell Lines	Host System	Preferred Model	Key Endpoints
Early efficacy screening and dose exploration	MCF-7, T47D, ZR-75-1, BT-474, HCC1954, MDA-MB-231, MDA-MB-468, SUM159, HCC1806	BALB/c nude, NOD-SCID, NSG	Subcutaneous CDX	TGI, RTV, terminal tumor weight, body weight, Ki67, apoptosis, target expression, PK/PD.
HR+/HER2- endocrine therapy research	MCF-7, T47D, ZR-75-1	BALB/c nude, NSG, usually with estrogen support	ER-positive subcutaneous CDX, escalation to mammary fat pad orthotopic model when needed	ER, PR, Ki67, pRB, TGI, RTV, endocrine drug response, long-term dosing window.
SERD / ER degradation / CDK4/6 combination	MCF-7, T47D, ZR-75-1, ESR1-related resistant derivatives	BALB/c nude, NSG, with estrogen regulation	HR+ CDX for early screening, resistant or long-term dosing models for deeper evaluation	ER degradation, pRB, cell cycle, Ki67, regrowth after withdrawal, resistance-related markers.
HER2-positive targeted agents and ADC early screening	BT-474, HCC1954	BALB/c nude, NOD-SCID, NSG; BT-474 usually requires estrogen support	HER2-positive subcutaneous CDX, orthotopic or brain metastasis model for confirmation	HER2 expression, TGI, RTV, ADC tissue distribution, apoptosis, PK/PD.
HER2-low / HER2-ultralow ADC research	HER2-low or HER2-ultralow stratified human breast cancer models	BALB/c nude, NSG	HER2-low stratified CDX, orthotopic/metastasis validation when needed	HER2 IHC stratification, ADC distribution, bystander effect, TGI, tissue exposure.
TNBC invasion and efficacy screening	MDA-MB-231, MDA-MB-468, SUM159, HCC1806	BALB/c nude, NOD-SCID, NSG	TNBC subcutaneous CDX, mammary fat pad orthotopic model for confirmation	TGI, RTV, Ki67, apoptosis, TROP2, EGFR, invasion and metastasis markers.
TROP2 ADC / TNBC ADC programs	MDA-MB-231, MDA-MB-468, SUM159, HCC1806 and TROP2-positive lines	BALB/c nude, NSG	Target-positive CDX, orthotopic and metastasis models for deeper evaluation	TROP2 expression, ADC tissue distribution, TGI, apoptosis, lung metastasis, survival.
Mammary fat pad orthotopic microenvironment	MCF-7-luc, T47D-luc, BT-474-luc, HCC1954-luc, MDA-MB-231-luc; 4T1-luc, EMT6, E0771-luc	BALB/c nude, NOD-SCID, NSG; BALB/c or C57BL/6 immunocompetent mice	Orthotopic mammary fat pad model	Orthotopic burden, BLI, local invasion, lymph node metastasis, lung metastasis, survival.
Lung metastasis research	4T1-luc, MDA-MB-231-LM2, 4175	BALB/c immunocompetent mice or BALB/c nude, NSG	Tail vein lung colonization model or orthotopic spontaneous lung metastasis model	Lung nodule count, lung weight, BLI, lung histopathology, survival.
Brain metastasis and BBB exposure research	MDA-MB-231-BrM2, JIMT-1-Br and brain metastasis derivatives	BALB/c nude, NOD-SCID, NSG	Left ventricle / carotid artery brain metastasis or intracranial inoculation model	MRI, BLI, brain metastatic burden, survival, brain edema, neurobehavior, brain tissue drug concentration.
Bone metastasis / bone pain / bone destruction	MDA-MB-231-BoM, 4T1 and bone-tropic derivatives	BALB/c nude, NSG or BALB/c immunocompetent mice	Left ventricle injection or tibial/femoral inoculation model	micro-CT, X-ray, bone destruction score, pain behavior, bone histopathology, survival.
Immunotherapy / TME remodeling	4T1, EMT6; E0771	BALB/c immunocompetent mice; C57BL/6 immunocompetent mice	Syngeneic immunocompetent subcutaneous screening, orthotopic model for confirmation	CD8/Treg, myeloid cell profile, PD-L1, cytokines, survival, metastatic burden.
TCE / CAR-T/NK / human immune-dependent therapies	MCF-7, T47D, BT-474, HCC1954, MDA-MB-231, MDA-MB-468, SUM159, HCC1806	huPBMC or huHSC-reconstituted NSG/NOG mice	Humanized immune model	hCD45, hCD3, hCD8, hNK, T cell activation, cytokines, CRS/xGvHD risk.
Postoperative relapse / MRD clearance	4T1-luc, E0771-luc, MDA-MB-231-luc	BALB/c immunocompetent, C57BL/6 immunocompetent, or immunodeficient mice	Orthotopic mammary fat pad model with surgical resection and follow-up	Local relapse, lung metastasis, time to relapse, survival, MRD-related markers, immune infiltration.

Comprehensive Test and Data Analysis Platform

For breast cancer programs focused on molecular subtyping and brain/bone metastasis evaluation, we configure TGI, RTV, terminal tumor weight, BLI, MRI, micro-CT, survival, brain/bone metastatic burden, bone destruction score, ER/PR, HER2, TROP2, pRB, pAKT, pS6, and brain/bone tissue exposure, forming an integrated data chain linking molecular subtyping, metastasis evaluation, and PK/PD.

Multimodal In Vivo Imaging

IVIS Spectrum photon bioluminescence quantification for mammary fat pad orthotopic tumors and lung metastasis tracking
7.0T small-animal high-field MRI for brain metastatic lesion scanning and BBB-related evaluation
micro-CT 3D reconstruction for osteolysis, bone mineral density, and bone destruction scoring

Pathology and IHC/IF Staining

ER / PR / HER2 / TROP2 receptor status and target expression assessment
pRB / pAKT / pS6 pathway and Ki67 / Cleaved-Caspase 3 index
mIF multiplex immunofluorescence for in situ target and breast TME quantification

TME Microenvironment and Immune Profiling

Breast tumor TILs (CD4+ / CD8+ / Treg) infiltration ratio analysis
TAM (M1 / M2) and MDSC suppressive subsets
Cytokine storm (IFN-γ / IL-6) CBA suspension array

Access Our Breast Cancer Model Library

Breast Cancer Cell Line Panel

Alfa Cytology's breast cancer cell line panel covers five key areas, including molecular subtyping, driver genes, target expression, metastasis research, and immuno-oncology, enabling cell line selection and matching based on molecular background, receptor status, target expression, and immune system requirements.

HR+/HER2- Endocrine Therapy-Related Cell Lines

MCF-7: a classic ER-positive model suitable for endocrine therapy, SERD, ER degraders, CDK4/6 combination, and long-term dosing studies.
T47D: an ER-positive, PR-positive model suitable for endocrine therapy, PI3K/AKT/mTOR pathway, and long-term dosing studies.
ZR-75-1: an ER-positive model suitable for endocrine therapy, ER pathway, and CDK4/6 combination research.

HER2-Positive and HER2-Low ADC-Related Cell Lines

BT-474: a HER2-high model suitable for HER2-targeted agents, HER2 ADCs, brain metastasis, and trastuzumab combination studies. Usually requires estrogen support.
HCC1954: a HER2-positive model suitable for HER2 ADCs, bispecifics, and resistance research.
HER2-low / HER2-ultralow stratified models: suitable for HER2-low ADC, bystander effect, and target expression stability studies. HER2-high models cannot substitute for HER2-low programs.

TNBC Invasion and ADC-Related Cell Lines

MDA-MB-231: a TNBC high-invasion model suitable for TROP2 ADCs, EGFR pathway, lung/bone metastasis, and invasion mechanism research.
MDA-MB-468: a TNBC model suitable for EGFR-high expression, TROP2 ADCs, and basic efficacy studies.
SUM159: a TNBC model suitable for invasion, metastasis, and ADC research.
HCC1806: a TNBC model suitable for TROP2 ADCs, EGFR pathway, and invasion research.

Immuno-Oncology-Related Cell Lines

4T1 / 4T1-luc: a BALB/c background syngeneic model suitable for immune checkpoint, STING, radiotherapy combination, and TME research.
EMT6: a BALB/c background syngeneic model suitable for immunotherapy and TME research.
E0771 / E0771-luc: a C57BL/6 background syngeneic model suitable for immunotherapy, TME, and relapse research.
Human breast cancer cell lines + huPBMC / huHSC: suitable for TCE, CAR-T/NK, human checkpoint, and human immune-dependent programs.

Metastasis Research-Related Cell Lines

MDA-MB-231-LM2, 4175: lung metastasis models suitable for tail vein lung colonization or orthotopic spontaneous lung metastasis research.
MDA-MB-231-BrM2, JIMT-1-Br: brain metastasis models suitable for left ventricle/carotid artery injection or intracranial inoculation models.
MDA-MB-231-BoM, 4T1: bone metastasis models suitable for left ventricle injection or tibial/femoral inoculation models.

Target Expression-Related Cell Lines

ER/PR: MCF-7, T47D, ZR-75-1.
HER2: BT-474, HCC1954.
TROP2: MDA-MB-231, MDA-MB-468, SUM159, HCC1806.
Target expression should be re-verified in vitro, after tumor formation, and at the endpoint stage to avoid misinterpretation due to target drift.

Breast Cancer Animal Model Panel

Alfa Cytology provides end-to-end breast cancer animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across HR+/HER2-, HER2-positive, HER2-low, and TNBC research. Each model can be customized to match your program's molecular subtype, driver gene, target expression, immune requirements, and metastatic organ scenario, from early screening to clinical relevance validation.

Subcutaneous Xenograft Model (CDX)

Subcutaneous CDX models typically involve inoculating human breast cancer cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume.

HR+/HER2- cell lines: MCF-7, T47D, ZR-75-1
HER2-positive cell lines: BT-474, HCC1954
TNBC cell lines: MDA-MB-231, MDA-MB-468, SUM159, HCC1806

Model characteristics
Subcutaneous CDX is suitable for early efficacy studies, target validation (e.g., ER, PR, HER2, TROP2, EGFR), dose exploration, PK/PD studies, and resistance and combination therapy research. However, this model cannot fully reflect the mammary fat pad orthotopic microenvironment, breast tissue exposure, brain/bone metastasis, lymph node metastasis, or intact immune responses.

Modeling and dosing timelines
Palpable tumor volumes suitable for enrollment are typically reached 1–3 weeks after inoculation, and stratified randomization by tumor volume is recommended. The conventional treatment observation period is usually 2–4 weeks; for special projects (resistance, sustained-release formulations, ADCs, or antibody drugs), this can be extended according to pharmacokinetic and toxicity windows. For resistance, recurrence, or sustained suppression studies, a post-treatment withdrawal observation period can be added to record tumor regrowth and regrowth rate.

Detection endpoints

Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival
Molecular mechanism layer: Ki67, cleaved caspase-3, TUNEL, ER, PR, HER2, TROP2, pRB, pAKT, pS6, and DNA damage markers
PK/PD layer: Plasma drug concentration, tumor tissue concentration, target occupancy, pathway inhibition, and ADC tissue distribution
Safety layer: Body weight, complete blood count, liver and kidney function, and major organ pathology

Recommended positive controls
For HR+/HER2- programs, tamoxifen, fulvestrant, or palbociclib can be selected; for HER2-positive programs, trastuzumab, T-DM1, or trastuzumab deruxtecan can be used; for TNBC programs, chemotherapy (taxane, platinum) or TROP2 ADC references can be selected. Specific doses should be adjusted based on model and administration route.

Mammary Fat Pad Orthotopic Model

Mammary fat pad orthotopic models typically involve inoculating tumor cells into the mammary fat pad to mimic the breast organ microenvironment, often using luc-labeled cells for dynamic monitoring.

HR+/HER2- orthotopic models: MCF-7-luc, T47D-luc, usually requiring estrogen support
HER2-positive orthotopic models: BT-474-luc, HCC1954-luc
TNBC orthotopic models: MDA-MB-231-luc; syngeneic models 4T1-luc, E0771-luc

Model characteristics
Suitable for breast organ microenvironment, local invasion, lymph node metastasis, spontaneous lung metastasis, and local drug delivery research. Orthotopic models are closer to clinical scenarios than subcutaneous models, but have lower throughput, complex procedures, and high inter-batch variability, and are not suitable as the highest-throughput early screening platform. Early screening can first use subcutaneous CDX, followed by orthotopic validation.

Modeling and dosing timelines
Orthotopic models are typically observed for 3–8 weeks, depending on the cell line, hormone background, and tumor growth rate. Luc-labeled models can be longitudinally monitored by BLI. The treatment window is usually 2–6 weeks. Targeted agents, endocrine therapy, ADCs, and local drug delivery can be designed according to model burden and pharmacokinetic windows.

Detection endpoints
Tumor burden layer: BLI, orthotopic tumor volume, mammary gland weight, tumor area, and survival

Local invasion layer: Local infiltration, lymph node metastasis, lung metastasis, and local pathology
Breast microenvironment layer: TILs, TAM, MDSC, cytokines, and immune infiltration
Drug exposure layer: Plasma drug concentration, tumor tissue concentration, and local tissue exposure

Recommended positive controls
For HR+/HER2- programs, endocrine therapy references can be set; for HER2-positive programs, trastuzumab or ADC references can be set; for TNBC programs, chemotherapy or ADC references can be set; for immunotherapy programs, anti-PD-1 or anti-PD-L1 references can be set.

Lung Metastasis Model

Lung metastasis models involve injecting tumor cells via tail vein or using orthotopic spontaneous metastasis to colonize the lung, used to study lung colonization, lung microenvironment, and anti-metastasis treatment scenarios.

Model characteristics
This model is suitable for lung colonization, post-metastasis treatment, and anti-metastasis strategy research. Tail vein models primarily address lung colonization after circulation, while orthotopic spontaneous metastasis models are closer to the natural metastatic process but have longer cycles.

Modeling and dosing timelines
Lung metastasis models can be established via tail vein injection or orthotopic spontaneous metastasis, using commonly applied cell lines such as 4T1-luc, MDA-MB-231-LM2, and 4175. Dosing schedules should be designed according to model windows and animal tolerance. Tail vein models typically have a modeling window of 1–4 weeks, whereas orthotopic spontaneous metastasis models are typically observed for 4–8 weeks.

Detection endpoints
Lung nodule count, lung weight, BLI, lung histopathology, and survival

Recommended positive controls
For lung metastasis programs, chemotherapy or anti-metastasis references can be set.

Brain Metastasis Model

Brain metastasis models can be established by injecting tumor cells via left ventricle, carotid artery, or intracranial inoculation to colonize the brain, used to study brain colonization, BBB penetration, and intracranial efficacy scenarios. Commonly used cell lines include MDA-MB-231-BrM2 and JIMT-1-Br.

Model characteristics
This model is suitable for brain colonization, BBB penetration, intracranial efficacy, and brain microenvironment research. Left ventricle or carotid artery models are more suitable for studying BBB penetration and brain colonization, while intracranial inoculation models are more suitable for intracranial efficacy and brain tissue exposure evaluation.

Modeling and dosing timelines
The observation period for brain metastasis models is typically 2–8 weeks, and the treatment window should be determined based on BLI or MRI signals; delayed dosing may affect endpoints due to neurological symptoms.

Detection endpoints
MRI/BLI, brain metastatic burden, survival, neurobehavior, brain edema, brain tissue pathology, and brain tissue drug concentration

Recommended positive controls
For brain metastasis programs, TKI or ADC references can be set.

Bone Metastasis Model

Bone metastasis models can be established by injecting tumor cells via left ventricle or tibial/femoral inoculation to colonize the bone, used to study bone colonization, bone microenvironment, and bone destruction scenarios. Commonly used cell lines include MDA-MB-231-BoM and 4T1.

Model characteristics
This model is suitable for bone colonization, bone microenvironment, and bone destruction research. Left ventricle injection models reflect bone colonization after systemic dissemination, while tibial/femoral inoculation models reflect local bone microenvironment research.

Modeling and dosing timelines
Bone metastasis models require dosing schedules designed according to model windows and animal tolerance. Left ventricle models are typically observed for 3–6 weeks; intrabone inoculation models are typically observed for 2–5 weeks.

Detection endpoints
micro-CT, X-ray, bone destruction score, bone density, TRAP staining, bone tissue pathology, bone pain behavior, and survival

Recommended positive controls
For bone metastasis programs, chemotherapy, targeted agents, radiotherapy combination, or bone protection references can be set.

Syngeneic Immunocompetent Models

Syngeneic immunocompetent models retain the host immune system and are suitable for immunotherapy, radiotherapy combination, STING, cytokines, oncolytic viruses, and TME mechanism research.

4T1 / 4T1-luc: BALB/c background, suitable for immune checkpoint, STING, radiotherapy combination, and TME research
EMT6: BALB/c background, suitable for immunotherapy and TME research
E0771 / E0771-luc: C57BL/6 background, suitable for immunotherapy, TME, and relapse research

Model characteristics
Retains an intact immune system, suitable for immune checkpoint, STING, cytokine, radiotherapy combination, TME remodeling, and immune resistance research. However, murine tumors differ from human tumors, and human target ADCs, TCE, and CAR-T/NK programs cannot fully rely on syngeneic models.

Detection endpoints
TGI, BLI, orthotopic tumor burden, survival, CD8/Treg, MDSC, macrophages, DC cells, PD-L1, IFN-γ, Granzyme B, and tumor tissue immunophenotyping.

Recommended positive controls
anti-PD-1, anti-PD-L1, anti-CTLA-4 can be administered intraperitoneally at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks. STING agonists, cytokines, or radiotherapy combinations should be individually designed according to mechanism.

Humanized Immune Models

Humanized immune models reconstruct the human immune environment by infusing human immune cells or human hematopoietic stem cells into immunodeficient mice, suitable for TCE, CAR-T/NK, human immune checkpoints, and human immune-dependent mechanism validation.

huPBMC model: Established by infusing human peripheral blood mononuclear cells into immunodeficient mice to create a short-term human immune effector environment, which can be combined with human breast cancer CDX; modeling is relatively rapid and suitable for short-cycle validation
huHSC model: Reconstructs a relatively long-term human immune system via human hematopoietic stem cells; the cycle is longer, but it is more suitable for complex immune microenvironment and long-term mechanism research

Model characteristics
This model is suitable for TCE, CAR-T/NK, human immune checkpoints, immune resistance, complex combination therapy, and human immune microenvironment mechanism research. However, humanized models are costly, highly variable, and subject to significant donor differences, with risks of xGvHD or cytokine release; they are not recommended as large-scale early screening models.

Detection endpoints

huPBMC: hCD45, hCD3, hCD4, hCD8, NK cells, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, and xGvHD manifestations
huHSC: Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology

Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanistic references. TCE, CAR-T, or CAR-NK projects should include target-positive, target-negative, effector cell controls, and irrelevant TCE controls. Cell therapy doses are often designed on the order of 10⁶–10⁷ cells/mouse.

Drug Resistance and Recurrence Research Models

Drug resistance and recurrence research models use resistant cell lines, long-term dosing induction, withdrawal relapse observation, or recurrence models to address first-line resistance, later-line resistance, lineage switching, and re-treatment sensitivity questions.

Endocrine resistance: MCF-7 resistant derivatives, T47D resistant derivatives, ESR1-mutant models
HER2 ADC resistance: BT-474 or HCC1954 resistant derivatives
TNBC resistance: MDA-MB-231 resistant lines, SUM159 resistant lines

Model characteristics
This model is suitable for resistance mechanism, combination therapy, later-line treatment, and drug combination prioritization research.

Modeling and dosing timelines
After efficacy reaches suppression, dosing can be withdrawn to observe tumor regrowth time, regrowth rate, and molecular marker changes; re-challenge with the original regimen, alternative targeted agents, ADCs, immune combinations, or chemotherapy combinations can be set up to observe sensitivity changes after recurrence.

Detection endpoints
TGI, regrowth rate, ER/PR/HER2 expression changes, pRB, pAKT, pS6, ESR1 mutation, TROP2 expression retention, ctDNA, tumor tissue drug concentration, and regrowth curves.

Recommended positive controls
For HR+ resistance programs, fulvestrant or CDK4/6 inhibitor references can be set; for HER2 resistance programs, T-DXd or tucatinib references can be set; for TNBC resistance programs, chemotherapy or ADC references can be set. Specific doses should be designed based on resistance phenotype and model window.

How to Select the Right Model for Your Program?

By Molecular Subtype

By Drug Type

By Research Objective

By Route of Administration

By Development Pathway

HR+/HER2- endocrine therapy programs: Prioritize MCF-7, T47D, and ZR-75-1 for endocrine therapy, SERD, ER degrader, and CDK4/6 combination studies.
HER2-positive programs: Prioritize BT-474 and HCC1954 for HER2-targeted agents, HER2 ADCs, bispecifics, and brain metastasis research.
HER2-low / HER2-ultralow ADC programs: Select models with well-defined stratification and stable in vivo target expression; do not substitute with HER2-high models.
TNBC programs: Prioritize MDA-MB-231, MDA-MB-468, SUM159, and HCC1806 for TROP2 ADCs, EGFR pathway, and invasion/metastasis research.
SERD / ER degradation / CDK4/6 combination programs: Start with HR+ CDX and incorporate ESR1-related resistant derivatives or long-term dosing models as needed.
Metastasis research programs: For lung metastasis, consider 4T1-luc, MDA-MB-231-LM2, and 4175; for brain metastasis, consider MDA-MB-231-BrM2 and JIMT-1-Br; for bone metastasis, consider MDA-MB-231-BoM and 4T1.

Chemotherapy and cytotoxic agents: Start with subcutaneous CDX; taxanes, platinum agents, and anthracyclines can serve as references.
Endocrine therapy and CDK4/6 combination: Prioritize MCF-7, T47D, and ZR-75-1; evaluate ER, PR, Ki67, pRB, and regrowth after withdrawal.
HER2-targeted agents and ADCs: Strictly match HER2 expression level. For ADC programs, focus on target expression stability, internalization, bystander effect, and tissue exposure.
TROP2 ADC / TNBC ADC: Confirm TROP2 expression stability first, then verify target retention in subcutaneous, orthotopic, or metastasis models.
Immunotherapy: Prioritize 4T1, EMT6, and E0771 syngeneic immunocompetent models. If the program is highly dependent on the human immune system, escalate to huPBMC or huHSC humanized models.
TCE and CAR-T/NK: Combine humanized models, in vitro killing assays, target validation, and cytokine release risk assessment.

Rapid tumor shrinkage and PK/PD: Prioritize subcutaneous CDX. Key endpoints include TGI, RTV, terminal tumor weight, body weight, and PK/PD.
Mammary fat pad orthotopic microenvironment: Prioritize orthotopic models. Key endpoints include orthotopic burden, BLI, local invasion, lymph node metastasis, and survival.
Lung metastasis: Prioritize tail vein lung colonization or orthotopic spontaneous lung metastasis models. Key endpoints include lung nodule count, lung weight, BLI, and lung pathology.
Brain metastasis: Prioritize left ventricle/carotid artery injection or intracranial inoculation models. Key endpoints include MRI/BLI, brain metastatic burden, brain edema, neurobehavior, and brain tissue exposure.
Bone metastasis: Prioritize left ventricle injection or tibial/femoral inoculation models. Key endpoints include micro-CT, bone destruction score, bone pain behavior, and bone histopathology.
Tumor immune microenvironment: Prioritize syngeneic immunocompetent or humanized models. Key endpoints include CD8/Treg, TAM, MDSC, cytokines, and immune infiltration.
Resistance and relapse: Use resistant derivatives, long-term dosing-induced models, or withdrawal relapse observation. Key endpoints include time to relapse, ER/HER2 expression changes, resistance markers, and retreatment sensitivity.

Systemic administration: Oral, intraperitoneal, intravenous, and subcutaneous dosing are suitable for subcutaneous CDX, orthotopic, metastasis, and immune models.
Local administration: Local injection, intratumoral dosing, and mammary local delivery are better suited to orthotopic models.
Brain metastasis administration: Brain metastasis programs should consider BBB penetration and brain tissue exposure. After systemic dosing, measure brain tissue drug concentration; intracranial models are better suited for direct evaluation of intracranial efficacy.
Combination immunotherapy dosing: Set dosing sequence based on mechanism.
Cell therapy dosing: For CAR-T/NK or TCE programs, set dosing timing based on tumor burden, target expression, human immune reconstitution, and safety window.

Endocrine therapy pathway: MCF-7/T47D/ZR-75-1 subcutaneous CDX early screening → orthotopic model validation → long-term dosing or withdrawal rechallenge model for deeper evaluation.
HER2 program pathway: HER2-positive CDX early screening → orthotopic or brain metastasis model validation → resistance or relapse model for deeper evaluation.
TNBC and TROP2 ADC pathway: Target-positive CDX ranking → orthotopic model validation → lung/bone metastasis model confirmation → humanized model confirmation when needed.
Immunotherapy pathway: Syngeneic subcutaneous early screening → syngeneic orthotopic or metastasis model validation → immune profiling → humanized model confirmation when needed.
Resistance and relapse pathway: Sensitive model establishment → long-term dosing induction → withdrawal relapse observation → retreatment sensitivity evaluation.

Why Alfa Cytology?

Receptor Status & Subtype-Driven Modeling
Breast cancer treatment hinges on molecular classification (HR+/HER2-, HER2+, and TNBC). Alfa Cytology designs tailored evaluation pathways based on receptor expression (ER, PR, HER2) and driver backgrounds (PIK3CA, BRCA1/2, TP53), preventing cross-subtype misinterpretation.

Stratified Cell Line & Model Directory
Model matching dictates translational relevance for endocrine, targeted, and IO therapies. Alfa Cytology helps clients select robust systems, such as MCF-7, T47D, SK-BR-3, MDA-MB-231, 4T1, and E0771, based on hormone dependency, HER2 amplification, metastatic capacity, and immune requirements.

Mammary Fat Pad Orthotopic & Organ Metastasis Models
Subcutaneous CDX models miss local stromal interactions, lymphatic spread, and organ tropism. Alfa Cytology helps clients generate high-fidelity evidence through orthotopic mammary fat pad implantation and spontaneous organ metastasis models (bone, brain, lung).

Target Validation & Integrated PK/PD Workflows
Programs targeting ER/SERD, CDK4/6, HER2 ADCs, or immunotherapies require longitudinal endocrine or immune contexture monitoring. Alfa Cytology configures hormone pellet support, biomarker kinetics, and integrated PK/PD workflows for complete therapeutic profiling.

At Alfa Cytology, we are committed to the research and study of breast cancer, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. For more information about our breast cancer research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.

Reference

Milano, A. F. (2023). Breast Cancer: 20-Year Comparative Mortality and Survival Analysis by Age, Sex, Race/Ethnicity, Stage, Grade, Disease Duration, Selected ICD-O-3 Oncophenotypes, and Cohort Entry Time-Period: A Systematic Review of 656,501 Cases for Diagnosis Years 1975-2019:(SEER* Stat 8.4. 0.1). Journal of Insurance Medicine, 50(2), 80-122.

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.